Kaken Pharmaceutical Co., Ltd. provided consolidated earnings guidance for the six months and full year ending March 31, 2021. For the six months, the company expects net sales of JPY 41,000 million, operating profit of JPY 10,900 million, profit attributable to owners of parent of JPY 7,900 million and basic earnings per share of JPY 203.26. For the full year, the company expects net sales of JPY 82,900 million, operating profit of JPY 20,800 million, profit attributable to owners of parent of JPY 15,000 million and basic earnings per share of JPY 385.94.